You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Merck delivers vital data on evobrutinib

Merck has announced updated four-year safety and efficacy data for its relapsing multiple sclerosis (RMS) therapy, evobrutinib.